Pilot trial of iBDecide: Evaluating an online tool to facilitate shared decision making for adolescents and young adults with ulcerative colitis.
Matula, KA; Minar, P; Daraiseh, NM; Lin, L; Recker, M; Lipstein, EA.
Health Expectations.
2022.
Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis.
Whaley, KG; Xiong, Y; Karns, R; Hyams, JS; Kugathasan, S; Boyle, BM; Walters, TD; Kelsen, J; LeLeiko, N; Shapiro, J; et al.
Clinical Gastroenterology and Hepatology.
2022.
Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis.
Clarkston, K; Karns, R; Jegga, AG; Sharma, M; Fox, S; Ojo, BA; Minar, P; Walters, TD; Griffiths, AM; Mack, DR; et al.
Journal of Crohn's and Colitis.
2022.
iBDecide: A web-based tool to promote engagement in shared decision-making among adolescents with ulcerative colitis.
Daraiseh, NM; Black, A; Minar, P; Meisman, A; Saxe, M; Lipstein, EA.
Patient Education and Counseling.
2022;
105:1628-1633.
Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn's Disease.
Miller, TL; Schuchard, J; Carle, AC; Forrest, CB; Kappelman, MD; Adler, J; Ammoury, RF; Bass, D; Bass, J; Benkov, K; et al.
Journal of Pediatrics.
2022;
242:86-92.e3.
Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease.
Colman, RJ; Xiong, Y; Mizuno, T; Hyams, JS; Noe, JD; Boyle, B; D’Haens, GR; van Limbergen, J; Chun, K; Yang, J; et al.
Alimentary Pharmacology and Therapeutics.
2022;
55:593-603.
Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.
Colman, RJ; Tsai, YT; Jackson, K; Boyle, BM; Noe, JD; Hyams, JS; D'Haens, GR A M; Van Limbergen, J; Rosen, MJ; Denson, LA; et al.
Inflammatory Bowel Diseases.
2021;
27:1045-1051.
Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease.
Xiong, Y; Mizuno, T; Colman, R; Hyams, J; Noe, JD; Boyle, B; Tsai, YT; Dong, M; Jackson, K; Punt, N; et al.
Clinical Pharmacology and Therapeutics.
2021;
109:1639-1647.
Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease.
Hellmann, J; Etter, RK; Denson, LA; Minar, P; Hill, D; Dykes, DM; Rosen, MJ.
Pediatric Quality and Safety.
2021;
6.
Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients.
Colman, RJ; Portocarrero-Castillo, A; Chona, D; Hellmann, J; Minar, P; Rosen, MJ.
Inflammatory Bowel Diseases.
2021;
27:507-515.